Melanocortin Peptides: POMC, Receptors, Agonists, and Antagonists
Melanocortin peptides are defined by the POMC–melanocortin receptor system, not by a broad outcome such as weight change, pigmentation, or sexual behavior. The endogenous members are adrenocorticotropic hormone (ACTH) and α-, β-, and γ-melanocyte-stimulating hormone (MSH). Their targets are five related G-protein-coupled receptors, MC1R through MC5R. Synthetic members include receptor agonists, analogs engineered for greater stability or selectivity, and antagonists used to separate one receptor’s contribution from another.
The practical reading rule is simple: a molecule belongs in this class when credible pharmacology shows that it directly activates or blocks a melanocortin receptor. Sharing a downstream phenotype with MC4R signaling does not establish class membership. The core five-receptor and POMC framework is summarized in a receptor-pharmacology review (Cai and Hruby, 2016).
Research context: This page is for research and educational purposes. It does not provide medical advice, personal-use instructions, product sourcing, or recommendations to use any peptide or drug.
Class at a Glance
| Question | Short answer | Why it matters |
|---|---|---|
| What creates the endogenous ligands? | Tissue-specific processing of pro-opiomelanocortin (POMC) | The same precursor yields different peptide mixtures in different tissues |
| Which receptor is the ACTH receptor? | MC2R | MC2R is unusual because ACTH is its activating melanocortin ligand and receptor function depends on MRAP |
| Which receptors recognize MSH peptides? | Primarily MC1R, MC3R, MC4R, and MC5R | Relative potency differs by ligand, receptor, species, and assay |
| Are all synthetic agonists selective? | No | MT-II and bremelanotide engage several receptor subtypes; setmelanotide and afamelanotide have more focused clinical pharmacology |
| Are all antagonists purely inhibitory at every subtype? | No | SHU9119 blocks MC3R and MC4R but acts as an agonist at MC1R and MC5R |
| Does FDA approval apply to the whole class? | No | Approval belongs to one product for a specific indication and population, not to related research compounds |
POMC Processing and the Endogenous Melanocortins
Pro-opiomelanocortin is a prohormone rather than one final signaling peptide. Prohormone convertases and additional processing enzymes cut and modify POMC in a tissue-dependent sequence. In pituitary corticotrophs, prohormone convertase 1/3 prominently generates ACTH and β-lipotropin. In tissues with prohormone convertase 2 activity, ACTH can be processed further to α-MSH and corticotropin-like intermediate peptide; other portions of POMC yield β-MSH, γ-MSH, and opioid peptides. This processing logic means that POMC expression alone does not prove that every POMC-derived peptide is present in the same cell or tissue (Yang, 2011).
The four endogenous melanocortin agonists share related sequence information but are not interchangeable:
- ACTH is a 39-amino-acid pituitary hormone whose N-terminal region contains the melanocortin pharmacophore. It activates MC2R in the adrenal cortex and can activate the other melanocortin receptors in pharmacological systems.
- α-MSH is a 13-amino-acid acetylated peptide generated from the ACTH sequence. It is a principal endogenous agonist at MC1R and an important signal at MC3R, MC4R, and MC5R.
- β-MSH is produced from the β-lipotropin region of human POMC. Its physiological relevance and sequence differ among species, an important limitation when moving between rodent and human research.
- γ-MSH peptides come from the N-terminal POMC region and often show relative preference for MC3R, but “preference” should not be read as exclusive receptor activity.
The conserved His-Phe-Arg-Trp sequence is central to activation of MC1R and MC3R–MC5R. MC2R recognizes ACTH through a more restrictive interaction and requires melanocortin-2-receptor accessory protein (MRAP) for normal trafficking and signaling. The endogenous system also includes the non-POMC proteins agouti signaling protein and agouti-related peptide (AgRP), which oppose signaling at selected receptor subtypes. This combination of peptide agonists and endogenous antagonists is an unusual feature of the melanocortin family (Cai and Hruby, 2016).
The diagram is a class map, not a claim that every ligand has equal potency at every connected receptor. Potency values can shift with species ortholog, expression system, receptor reserve, signaling readout, and accessory proteins.
MC1R–MC5R Receptor Map
All five melanocortin receptors are class A GPCRs that commonly signal through Gs, adenylyl cyclase, and cyclic AMP. That shared signaling architecture does not make their biology redundant. Tissue location, ligand preference, constitutive activity, accessory proteins, and noncanonical signaling all change the experimental result.
| Receptor | Representative expression | Endogenous ligand pattern | Best-established biological anchor | Interpretation caution |
|---|---|---|---|---|
| MC1R | Melanocytes; also reported in keratinocytes and immune-cell contexts | α-MSH and ACTH are prominent agonists; other melanocortins can activate it | Eumelanin synthesis and pigmentation responses | Skin expression is not its only reported context, and receptor variants alter signaling |
| MC2R | Primarily adrenal cortex | ACTH-dependent; MSH peptides do not substitute as conventional agonists | Adrenal steroidogenesis | Functional expression requires MRAP, so an isolated receptor assay can mislead |
| MC3R | Central nervous system and several peripheral tissues | γ-MSH, α-MSH, β-MSH, and ACTH show activity with assay-dependent rank order | Energy partitioning and neuroendocrine/immune research | MC3R biology cannot be inferred from MC4R results; truly selective ligands remain valuable tools |
| MC4R | Broad neuronal distribution, especially hypothalamic and autonomic circuits | α-MSH, β-MSH, and ACTH activate it; AgRP opposes basal and agonist-driven signaling | Energy balance, autonomic output, and behavior | Central effects are circuit-specific; a cell assay does not predict a whole-organism outcome |
| MC5R | Multiple peripheral tissues, including exocrine and immune-associated sites | Several MSH peptides and ACTH can activate it | Exocrine secretion and peripheral immune research | Broad expression and fewer subtype-selective tools leave many effects incompletely assigned |
This table lists representative rather than exclusive expression. For broader anatomy context, see the site’s endocrine system research guide, central nervous system research guide, and immune system research guide.
Why MC2R is the outlier
MC2R is often compressed into a generic five-receptor diagram, but it deserves separate handling. It is the adrenal ACTH receptor, has an unusually strict ligand requirement, and depends on MRAP for surface expression and signaling competence. A synthetic peptide that activates MC1R, MC3R, MC4R, and MC5R cannot be assumed to activate MC2R simply because all five receptors share ancestry.
Why MC3R and MC4R should not be merged
MC3R and MC4R are often written as “MC3/4R” because several classic tools engage both. That shorthand describes the tool more than the receptors. Knockout genetics, neural distribution, and ligand-development studies indicate distinct roles. The scarcity of highly selective MC3R probes has historically made attribution harder; medicinal-chemistry studies therefore report activity across receptor panels rather than treating MC3R selectivity as self-evident (Carotenuto et al., 2015).
Endogenous and Synthetic Ligand Comparison
The most useful way to compare melanocortin ligands is to separate origin, functional action, receptor profile, evidence role, and regulatory status. A familiar name or shared scaffold answers none of those questions by itself.
| Ligand | Origin or design | Functional profile | Receptor interpretation | Evidence or status |
|---|---|---|---|---|
| ACTH | Endogenous POMC product | Agonist | Activates MC2R and can activate MC1R, MC3R, MC4R, and MC5R | Endogenous hormone; approved ACTH products are separate regulated formulations |
| α-MSH | Endogenous peptide processed from ACTH | Agonist | Prominent at MC1R; active at MC3R, MC4R, and MC5R | Foundational physiological and laboratory ligand |
| β-MSH | Endogenous human POMC product | Agonist | Active across non-MC2 receptors with species and assay differences | Physiological relevance is species-sensitive |
| γ-MSH | Endogenous N-terminal POMC products | Agonist | Often relatively MC3R-preferring, not MC3R-exclusive | Useful in MC3R-focused physiology with selectivity controls |
| Agouti signaling protein | Endogenous paracrine protein | Antagonist and inverse-agonist behavior in selected systems | Strongly associated with MC1R opposition; activity at MC3R/MC4R depends on system | Physiological regulator, not a POMC cleavage product |
| Agouti-related peptide (AgRP) | Endogenous hypothalamic protein | Antagonist and inverse agonist | Primarily opposes MC3R and MC4R | Key counter-signal to POMC neurons in energy-balance circuits |
| NDP-MSH / afamelanotide / Melanotan I | Linear α-MSH analog with Nle4 and D-Phe7 substitutions | Stable agonist | Experimental activity spans MC1R and MC3R–MC5R; clinical pharmacology emphasizes MC1R | These names refer to the same molecule, although naming follows research or clinical context |
| MT-II (Melanotan II) | Cyclized, shortened α-MSH analog | Nonselective agonist | Potent at MC1R, MC3R, MC4R, and MC5R; not an MC2R substitute | Laboratory and investigational tool; not FDA-approved |
| Bremelanotide (PT-141) | Cyclic melanocortin analog related to MT-II | Nonselective agonist | FDA label reports potency order MC1R, MC4R, MC3R, MC5R, MC2R; MC1R and MC4R are most relevant at approved exposure | FDA-approved product for one defined HSDD population; not blanket approval of MT-II or other analogs |
| Setmelanotide | Synthetic cyclic peptide | MC4R agonist with clinically focused selectivity | Designed to restore downstream MC4R-pathway signaling in genetically defined disease | FDA-approved product for specified rare genetic obesity populations; not general validation for every form of obesity |
| SHU9119 | Cyclic MT-II analog with D-Nal substitution | Mixed antagonist/agonist | Potent antagonist at MC3R and MC4R, while acting as an agonist at MC1R and MC5R | Experimental pharmacology tool; not FDA-approved |
Afamelanotide and NDP-MSH are not two separate analogs
NDP-MSH is the established experimental name for [Nle4, D-Phe7]-α-MSH, also called Melanotan I. Afamelanotide is the name used for that molecule in clinical development and the approved Scenesse product. Treating “NDP-MSH” and “afamelanotide” as separate compounds would double-count one peptide. FDA’s 2019 review identifies Scenesse as an MC1R agonist and structural analog of α-MSH (FDA risk review, October 4, 2019).
MT-II and bremelanotide are related, not interchangeable
MT-II is a cyclic pan-melanocortin research agonist. Bremelanotide is a related cyclic analog with its own characterized product, clinical program, and regulatory label. The FDA label describes bremelanotide as nonselectively activating several receptor subtypes and explicitly states that its clinical mechanism in HSDD is unknown. Therefore, receptor activity should not be rewritten as proof of one hypothalamic pathway or transferred to MT-II as clinical evidence (Vyleesi prescribing information, initial U.S. approval 2019; accessed September 4, 2026).
SHU9119 demonstrates why “antagonist” needs a receptor name
Calling SHU9119 simply “a melanocortin antagonist” is incomplete. It is a potent MC3R/MC4R antagonist but an MC1R/MC5R agonist. A change at one scaffold position can reverse efficacy at selected subtypes without doing so across the family. That mixed profile is documented in receptor-focused medicinal-chemistry literature (Hruby et al., 2011 review) and is why experiments should identify receptor, species, and readout alongside the ligand name.
How to Read Receptor Selectivity Claims
“Selective” is comparative. It means a ligand showed a measurable preference under stated conditions; it does not mean that every other receptor is silent in every tissue.
1. Binding and signaling are different measurements
A binding affinity value describes how strongly a ligand occupies a receptor in a particular assay. A functional potency value describes the concentration associated with a measured response, such as cyclic AMP accumulation. Receptor reserve can make a weakly binding ligand look functionally potent, while partial agonism can produce strong binding with a lower maximal response. Selectivity ratios should compare like with like.
2. Species orthologs can change rank order
Human, mouse, and rat melanocortin receptors are homologous but not pharmacologically identical. This matters especially when a tool is characterized in a recombinant human receptor panel and then used in an animal model. β-MSH biology also requires species awareness because rodent POMC processing does not mirror the human peptide set exactly.
3. Receptor expression changes apparent pharmacology
Overexpressed cell lines may have more receptor reserve than native tissue. MC2R additionally needs MRAP. Neural circuits introduce localization, transport, and network effects that a single-cell assay cannot reproduce. A result described as “MC4R-mediated” is strongest when supported by more than one line of evidence, such as a selective ligand plus genetic loss of receptor function.
4. Agonism can be pathway-biased
Gs–cyclic AMP is the canonical melanocortin readout, but receptors may recruit additional signaling and regulatory proteins. Two ligands with similar cyclic AMP values can differ in arrestin recruitment, receptor internalization, or longer-term transcriptional effects. A single assay should not be generalized into a total biological profile.
5. Exposure is part of selectivity
A receptor-selectivity ratio measured in vitro does not establish which tissues a peptide reaches. Stability, protein binding, local metabolism, and access to the central nervous system change which receptor populations can be engaged. Structural changes in NDP-MSH and MT-II were created partly to increase stability, but increased persistence does not itself confer subtype selectivity.
A rigorous receptor claim should therefore name: ligand identity, receptor subtype, species, assay, functional endpoint, comparator, and uncertainty.
Evidence and Regulatory Status Are Separate Questions
Melanocortin research spans biochemical assays, animal models, human trials, and approved medicines. Those layers answer different questions.
| Evidence layer | What it can establish | What it cannot establish alone |
|---|---|---|
| Receptor binding | Affinity under a defined assay condition | Functional activation, tissue exposure, or clinical benefit |
| Cell signaling | Agonism, antagonism, potency, efficacy, or bias in that system | Whole-organism selectivity or a therapeutic outcome |
| Animal physiology | Integrated effects in one species and model | Human effectiveness, human safety, or regulatory status |
| Human investigation | Findings in the studied population and endpoint | Transfer to an unstudied analog, indication, or population |
| Regulatory approval | A benefit–risk determination for a named product and labeled use | Class-wide endorsement or approval of research-only compounds |
Three FDA examples illustrate the distinction:
- Afamelanotide: FDA’s review identifies Scenesse as an MC1R agonist and documents approval in 2019 for increasing pain-free light exposure in adults with erythropoietic protoporphyria. This supports that product and indication, not aesthetic use of any peptide sharing an α-MSH scaffold (FDA review dated October 4, 2019).
- Bremelanotide: The official label identifies Vyleesi as a melanocortin receptor agonist approved in 2019 for acquired, generalized hypoactive sexual desire disorder in a defined premenopausal population. The label also says the mechanism by which it improves HSDD is unknown, a useful boundary against overconfident pathway narratives (FDA label, accessed September 4, 2026).
- Setmelanotide: Drugs@FDA records the original Imcivree approval on November 25, 2020. Its current labeled populations have changed through later supplemental actions, so claims about age and eligible genetic conditions should be checked against current labeling rather than copied from the original announcement (Drugs@FDA application 213793, accessed September 4, 2026).
MT-II and SHU9119 are presented in the cited literature as experimental receptor probes. Those pharmacology papers are not regulatory approvals. Their research role is categorically different from an approved product, even when an experimental ligand is structurally related to one.
What Does Not Establish Melanocortin Class Membership
Class boundaries prevent misleading comparisons. None of the following is sufficient on its own:
- an effect on body weight or food intake;
- a relationship to pituitary or hypothalamic biology;
- a peptide structure or injectable formulation;
- marketing alongside a known melanocortin analog;
- overlap in a downstream second messenger such as cyclic AMP;
- structural derivation from an unrelated hormone;
- a user report of pigmentation, appetite, or sexual effects.
Direct receptor pharmacology, supported by an appropriate assay and reproducible source, is the relevant criterion. Even then, the receptor subtype and functional direction—agonist, partial agonist, antagonist, or inverse agonist—must be stated.
Research Limits and Open Questions
MC3R physiology and selective tools
MC3R remains less completely resolved than MC4R in several domains. Ligands that separate MC3R from MC4R without meaningful activity at MC1R or MC5R are needed to attribute phenotypes cleanly. Discovery studies have produced more selective MC3R agonists, but model, species, and functional endpoint still matter (Carotenuto et al., 2015).
MC5R function outside classic exocrine models
MC5R is broadly reported in peripheral tissues, yet relatively few selective peptide probes are available. Mixed ligands can make an immune or secretory phenotype look like an MC5R effect when MC1R or MC3R is also active. Genetic and orthogonal pharmacology remain important.
Biased signaling and receptor context
Canonical cyclic AMP assays capture only one signaling dimension. Structural studies and newer signaling panels may distinguish ligands that stabilize different receptor states. Whether those differences predict clinically useful separation of effects remains a research question rather than an established class rule.
Translating rare-disease pathway rescue
Setmelanotide shows that downstream MC4R signaling can be clinically targeted in selected genetically defined disorders. That does not mean the same response should be expected in general polygenic obesity or in defects located downstream of MC4R. Genotype, intact pathway position, and labeled eligibility are part of the evidence.
Long-term and class-wide inference
Approved-product surveillance can inform the specific molecule and formulation observed. It cannot fill evidence gaps for MT-II, SHU9119, or another analog with different receptor occupancy and exposure. “Melanocortin peptide” is a mechanistic family label, not a shared safety profile.
A Researcher’s Appraisal Checklist
Before relying on a melanocortin claim, ask:
- Is the peptide identity unambiguous, including whether an alias names the same molecule?
- Is the claimed receptor subtype named rather than hidden behind “melanocortin activity”?
- Does the experiment measure binding, activation, blockade, or a whole-organism phenotype?
- Are receptor species and assay system reported?
- Is selectivity quantified against all relevant melanocortin receptors?
- Could an agonist at one subtype be an antagonist at another?
- Does the model establish tissue exposure or central access?
- Is human evidence separated from animal and cell evidence?
- Is regulatory language tied to a named product, population, and indication?
- Are current label claims dated and linked to an authoritative source?
Related Research Guides
- Endocrine system research guide — pituitary, adrenal, and hormone-signaling context
- Central nervous system research guide — neural receptor and circuit context
- Immune system research guide — interpreting immune-cell and inflammation models
References
- Cai M, Hruby VJ. The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases. Current Protein & Peptide Science. 2016. Full text.
- Yang Y. Structure, function and regulation of the melanocortin receptors. European Journal of Pharmacology. 2011. Full text.
- Carotenuto A, Merlino F, Cai M, et al. Discovery of Novel Potent and Selective Agonists at the Melanocortin-3 Receptor. Journal of Medicinal Chemistry. 2015. Full text.
- Hruby VJ, Cai M, Nyberg J, Dhanasekaran M. Approaches to the rational design of selective melanocortin receptor antagonists. Expert Opinion on Drug Discovery. 2011. Full text.
- Webb TR, Clark AJL. Minireview: The Melanocortin 2 Receptor Accessory Proteins. Molecular Endocrinology. 2010. Full text.
- FDA. Vyleesi (bremelanotide) prescribing information. Initial U.S. approval 2019; source accessed September 4, 2026. Official label.
- FDA Center for Drug Evaluation and Research. Scenesse (afamelanotide), NDA 210797, risk assessment and risk mitigation review. October 4, 2019. Official review.
- FDA. Drugs@FDA: Imcivree (setmelanotide), application 213793. Approval history; source accessed September 4, 2026. Official application record.
- Grieco P, Cai M, Han G, et al. Further structure–activity studies of lactam derivatives of MT-II and SHU9119: their activity and selectivity at human melanocortin receptors 3, 4, and 5. Peptides. 2007. DOI record.
- Sebag JA, Hinkle PM. Melanocortin-2 receptor accessory protein MRAP forms antiparallel homodimers. Proceedings of the National Academy of Sciences. 2007. Full text.